Moreover, it has been shown that pristimerin, a natural-occurring quinone methide triterpenoid with anticancer effects, inhibits glioblastoma progression by targeting two receptors, the protein tyrosine phosphatase, non-receptor type 1 (PTPN1), and Argonaute 2 (AGO2) via miR-542-5p [71]. Here, AGO2 is linked to glioblastoma.